Sangamo Therapeutics, Inc.
0R1D.L
Get informed when a big investor buys or sells
+ FollowMarket Cap$884.7M
Close$
Share Statistics
| Market cap | $884.70 Million |
|---|---|
| Enterprise Value | $884.69 Million |
| Dividend Yield | $- (NaN%) |
| Earnings per Share | $-0.44 |
| Beta | 1.4 |
| Outstanding Shares | 389,616,000 |
Return
| Return on Equity | -468187.69% |
|---|---|
| Return on Assets | -85789.41% |
| Return on Invested Capital | -87410.88% |
Valuation & Multiples
| P/E Ratio | - |
|---|---|
| PEG | - |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | 25.6 |
| Enterprise Value to EBIT | -7.04 |
| Enterprise Value to Net Income | -8 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0 |
Revenue Sources
No data
Insider Trades
Next Earnings Call
Expected Date
October 13, 2026
EPS Estimate
$-0.07
Average shareholder expectationRevenue Estimate
$7.50 M
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Sangamo Therapeutics Inc
142 employees
CEO: Alexander Macrae Sangamo Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the research and development of zinc finger proteins. The firm focuses on three therapeutic areas: inherited metabolic diseases, central nervous syste...